爱博医疗机器人 (Aibo Medical Robot) is a Shenzhen company focused on developing pan‑vascular vascular interventional surgical robots that support multiple procedure types including neuro, coronary and peripheral interventions. The company emphasizes original technology and med‑tech integration, using a modular design to enable multi‑instrument coordination, force‑feedback, low‑latency remote operation and broad consumable compatibility. Its first‑generation product has entered human clinical trials and the second generation is approaching qualification testing; the firm also demonstrated 5G‑based global remote operation in 2022. The company reports a large intellectual property portfolio (368 domestic and international patents, 134 granted) and deep clinical collaborations with leading experts and hospitals. Recent strategy and R&D plans include accelerating clinical enrollment for the new pan‑vascular robot, building an intelligent vascular intervention platform, strengthening talent and speeding commercialization and industrialization. Aibo Medical Robot develops modular vascular interventional surgical-robot systems that support multi-catheter and guidewire collaborative control and compound actions (push, rotate, push+rotate). The system is designed to match clinicians’ existing workflows, shorten learning curves, and reduce radiation exposure by enabling remote operation outside the cath lab. The product has iterated to a third generation, the company claims a patent portfolio of more than 100 domestic and international IP filings/approvals, and it has received over ¥50M in research funding. Aibo emphasizes miniaturization, light-weighting and cost reduction and plans to enter registration clinical trials this year. The company also reports tight clinical partnerships with top hospitals and a multidisciplinary team led by academician Guo Shuxiang and Dr. Guo Jian.

Total raised

$33M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2023